LETTERS TO THE EDITOR

SARS-CoV-2 infection and treatment in a cohort of patients with inborn errors of immunity

To the Editor,

Many authors recently reported the effect of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic on patients affected by Inborn Errors of Immunity (IEI). Although mostly experiencing a mild disease and the course of the infection is comparable or even less symptomatic than the general population, young male IEIs patients were more severely affected and more frequently admitted to intensive care unit compared with the age-matched healthy peers. Most viral variants were actually first described in immunocompromised patients. Indeed, impaired B and/or T cell function can be responsible for persisting viral shedding often observed in IEI patients with subsequent higher risk of persistent viral replication and mutation within the host. Noteworthily, in the last 2 years Inborn Errors of type I IFN immunity and autoantibody-mediated phenocopies of IEIs were identified as responsible for life-threatening COVID-19. These conditions were not considered in the studies about IEIs and SARS-CoV-2 infection. Predisposition to increased risk and most severe infection in IEI, despite a lack of clear data in favor of a high risk for progression to severe COVID-19, led the scientific community to recommend the use of early SARS-CoV-2-directed treatments to potentially reduce the incidence of long-lasting infection, as well as morbidity and mortality risk.

Casirivimab–imdevimab, also known as REGEN-COV, is an anti-spike mAb that has been authorized for the treatment of high-risk patients (>12 years of age, >40 kg) with mild-to-moderate COVID-19. Bamlanivimab, named LY-CoV555, then combined with etesevimab, showed a beneficial effect for accelerating the natural decline of the viral load over time. In December 2021, it was approved by FDA for patients<12 years.

Sotrovimab, formerly known as VIR-7831, is an engineered human mAb that neutralizes SARS-CoV-2. There are several data confirming the safety and efficacy in both adults and pediatric population.

We describe a cohort of 63 SARS-CoV-2-infected IEI patients, providing the first case series report on the early employment of anti-SARS-CoV-2 treatments with antiviral drugs and MAbs in these patients (Table S1). Thirty-nine patients were younger than 12 years (median age 9.5 years), whereas 24 were adults (median age 33 years). Male-to-female ratio was 1:1. Seven individuals have been previously reported. The distribution of SARS-CoV-2-infected IEI patients into International Union of Immunological Societies (IUIS) categories was similar to those described by Meyts et al. and Milito et al. (Figure 1) and also reflected the frequencies of each disease. In fact, 71% of patients belonged to second and third IUIS categories. Interestingly, 58% of IEIs were genetically determined and the most frequently involved pathways were those affecting T cell homeostasis: 22q11.2 deletion, STAT3 and ATM variants were addressed together as responsible for 25% of molecular IEI diagnoses in our cohort. Comorbidities were variable and, in some cases, influenced the clinical course of coronavirus infection and the therapeutic choice.

According to current guidelines, all patients affected by IEI are eligible for SARS-COV2 treatment. At the time of this manuscript, specific guidelines about the choice of the most suitable treatment for each patient were lacking. The criteria for treatment choice were based on the underlying IEI, the patient clinical conditions, the variety of concern (VOC), when available, or the current prevalence of resistant variants and drug’s availability in each center and patient’s age.

SARS-CoV-2 infection prevalence and incidence dramatically increased since the last months of 2021. Indeed, the number of SARS-CoV-2-positive IEI individuals reported in this manuscript is much higher compared with the cases previously reported. This mirrors the current epidemiology of coronavirus disease 2019 (COVID-19) in general population, characterized by a huge spread due to both the increasing prevalence of Omicron variant over Delta and the gradual softening of social restriction measures.

As reported in the first pandemic phase, most of our IEI patients did not develop severe COVID-19. In most of our patients, SARS-CoV-2 infection dated back no more than October 2021, and 15/17 tested subjects were infected by the Omicron variant. Therefore, it is possible to speculate that most cases were sustained by this variant, which has been reported to be less commonly related to severe complications. Indeed, 90% of our patients experienced a mild clinical course and only 6/63 (9.5%) showed a moderate/severe course: 4/6 were under 18 years and 5/6 presented important comorbidities that may have influenced the clinical course.

Francesca Conti, Lucia Pacillo contributed equally to this work and share first authorship.
Andrea Pession, Andrea Finocchi share last authorship.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2022 The Authors. Pediatric Allergy and Immunology published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
5/6 presented a moderate course including a del22 syndrome with associated CID and cardiopathy, a APDS patient with an ongoing lymphoma relapse, a CVID patient with IBD, a patient with CVID and associated osteochondrosis and one post-HSCT and kidney transplantation for Schimke syndrome with epilepsy and ischemic/hemorrhagical neurological events.

Only a 4-year-old male child with an unclassified IEI and a previous history of hemolytic uremic syndrome died 6 days after SARS-CoV-2 infection due to CMV-related acute respiratory distress syndrome, acute renal failure and cerebral edema despite MABs administration. Remarkably, 3 patients had SARS-CoV-2 infection after gene therapy (one after experimental gene therapy for WAS\textsuperscript{13}, and two after approved gene therapy for ADA deficiency); all patients experienced a favorable clinical course. A novel issue in our study was the cohort’s high anti-SARS-CoV-2 vaccination coverage: 59% of individuals had received at least two vaccine doses, with no significant adverse effects, while 38% had not received any vaccine. Nevertheless, vaccinal campaign did not seem to impact substantially on infection frequency and severity among the studied population, probably due to the availability of drugs' and patients' age.

Antivirals or neutralizing monoclonal antibodies were employed in 29/63 patients (46%). Antivirals and MABs were used in 5/29 and 25/29 cases, respectively. No serious adverse effects were observed. The therapy was proposed to each patient for which the medical staff was aware according to the eligibility criteria.\textsuperscript{9} Variability in the therapeutic strategies approach was mainly determined by drugs' availability in each center and patients’ age.

Notably, our report is also the first to describe the off-label use of MABs in pediatric patients below the age for which they were licensed (8/25 patients treated with MABs were <12 years of age).

Brown et al.\textsuperscript{15} recently described a cohort of 31 IEI patients, predominantly affected by humoral defects, with chronic or relapsing COVID-19, and showed a better response to combination of remdesivir plus MABs. In our study, non-standardized timing and antigenic/PCR methods determination for SARS-CoV-2 testing along with the
absence of a long-term follow-up did not allow an unbiased impact assessment of the efficacy of these early treatments. However, we did not observe substantial differences in terms of infection clearance (2 days spared) and symptom recovery (1 day spared) between treated and untreated patients (p-value 0.86); nevertheless, we observed a faster mean time clearance in patients who had received at least 2 vaccination doses respect to the rest of our IEI cohort (17 versus 24 days).

Overall, our experience confirms that COVID-19 has a mild clinical course in most patients with IEIs, yet a significant minority remains at a risk of severe disease. Early preventive therapies are frequently employed in this population, with good tolerance, even when used off-label for children under 12 years of age. Standardized protocol specifically set on IEI patients and information on pediatric doses, however, are lacking, possibly hindering access to these treatments.

ACKNOWLEDGMENTS
We would like to thank the patients, caregivers and clinic teams for their participation and kind support of this study. Open access funding provided by Ospedale Pediatrico Bambino Gesu.

FUNDING INFORMATION
This research received no external funding.

KEYWORDS
antiviral drugs, COVID-19, inborn errors of immunity, monoclonal antibodies, primary immunodeficiencies, SARS-COV2, treatment

CONFLICT OF INTEREST
The authors declare no conflict of interest.

ETHICAL APPROVAL
All patients or caregivers gave their informed consent prior to their inclusion in the study.

PEER REVIEW
The peer review history for this article is available at https://publons.com/publon/10.1111/pai.13833.
REFERENCES


SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.